Search results
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 5 hours agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap ...
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks via Yahoo Finance· 9 hours agopharmaceutical companies. It is designed to provide capital appreciation by thoroughly evaluating...
AbbVie buyout Cerevel marks trial win for Parkinson’s drug
Seeking Alpha· 6 days agoAbbVie's (ABBV) buyout target, Cerevel Therapeutics (CERE), announced positive data for its...
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 1 day agoSource: Author's elaboration, based on Takeda Pharmaceutical's 20-F. Entyvio sales were 227.6 billion yen in the third quarter of fiscal year 2023, an...
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
Zacks via Yahoo Finance· 7 days agoAbbVie is currently a Zacks Rank #3 (Hold). Looking at valuation, AbbVie is presently trading at a...
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Zacks via Yahoo Finance· 1 day agoLilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings...
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
BioPharma Dive via Yahoo Finance· 6 days agoFor AbbVie, the drug could help round out a portfolio of Parkinson’s medicines that includes the...
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
The Wall Street Journal· 6 days agoAbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when ...
AbbVie Inc. (NYSE:ABBV) to Post Q1 2024 Earnings of $2.21 Per Share, William Blair Forecasts
ETF DAILY NEWS· 5 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Research analysts at William Blair issued their Q1 2024 EPS estimates for AbbVie in a research note issued to investors ...
FY2025 EPS Estimates for AbbVie Inc. (NYSE:ABBV) Lowered by Analyst
ETF DAILY NEWS· 5 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Investment analysts at William Blair dropped their FY2025 EPS estimates for shares of AbbVie in a report released ...
